1. European Medicines Agency/91055/2013. 13 December 2012. Committee for Medicinal Products for Human Use (CHMP). Assesment report. Adasuve. International non-proprietary name: loxapine. Procedure No. EMEA/H/C/002400. URL: http://www.ema.europa.eu /docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002400/WC500139407.pdf. Zugriff am 31.07.2013.
2. Heel RC, Brogden RN, Speight TM, Avery GS. Loxapine: a review of its pharmacologica properties and therapeutic efficacy as an antipsychotic agent. Drugs. 1978 Mar;15(3):198–217.
3. Li Z, Ichikawa J, Meltzer HY. A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex an nucleus accumbens. Psychopharmacology (Berl). 2003 May;167(3):315–23. Epub 2003 Mar 28.
4. Herrick-Davis K, Grinde E, Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther. 2000 Oct;295(1):226–32.
5. Glazer WM. Does loxapine have „atypical“ properties? Clinical evidence. J Clin Psychiatry. 1999;60 Suppl 10:42–6.